PUBLIC COMPANY
save$ARMPArmata Pharmaceuticals, Inc.
$ARMPLos Angeles, CA, USupdated 21d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
- phase2Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
- phase2Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Mar 14, 26tax coverBirx Deborah · Chief Executive Officer4,919 sh
- Mar 14, 26tax coverKyme Pierre · Chief Business Officer1,030 sh
- Mar 9, 26grantKyme Pierre · Chief Business Officer183,142 sh
- Mar 9, 26grantHouse David Duane · SVP, Finance, and PFO109,885 sh
- Mar 9, 26grantPATTI JOSEPH M · 25,640 sh
- Mar 9, 26grantPeterson Todd C. · 25,640 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that